Bio-Rad Laboratories (BIO) stock is in focus after Q1 2026 results showed sales of US$592.1 million and a net loss of US$527.1 million, alongside weaker bioprocessing demand and cautious biotech spending.

The Q1 2026 net loss and reduced revenue outlook have been followed by a 7 day share price return of 8.14% decline and a year to date share price return of 15.71% decline, while the 1 year total shareholder return of 6.76% suggests longer term holders have had a different experience.

If this kind of volatility has you comparing opportunities in healthcare, it could be a good moment to scan for other research driven life sciences exposures using our 35 healthcare AI stocks.

With the stock down over the past year despite a recent net loss driven by its Sartorius stake and softer bioprocessing demand, you have to ask: is Bio-Rad now undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 19.9% Undervalued

Bio-Rad Laboratories' most followed narrative pegs fair value at $321.25 per share, compared with the last close of $257.32, framing a sizable valuation gap built on detailed earnings and margin assumptions.

Recent launch and expansion of the QX Continuum and QX700 Series ddPCR platforms, alongside the acquisition of Stilla Technologies, positions Bio-Rad to accelerate its share capture as demand grows for advanced molecular diagnostics and precision medicine tools; this is expected to drive ddPCR revenue growth and improve margins through higher consumable pull-through and broader assay adoption.

Curious what kind of revenue trajectory and margin reset could underpin that valuation gap? The narrative leans on slower top line growth, shifting profitability and a richer future earnings multiple that might surprise you.

Result: Fair Value of $321.25 (UNDERVALUED)

However, that upside story depends on weaker instrument demand easing and on gross margin pressure from higher material costs and underused manufacturing capacity not becoming a longer term drag.

Another Angle On Valuation

Those analyst narratives point to a fair value of $321.25, yet our check on the current P/E of 40.8x versus a fair ratio of 15.3x, the global Life Sciences average of 37.1x and a peer average of 54.5x paints a more cautious picture of what you are paying for every dollar of earnings. Which signal do you trust more when the story and the multiple disagree?

Next Steps

Mixed signals or early opportunity: either way it pays to move quickly, review the upside and downside cases, and weigh the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Bio-Rad has sharpened your focus, do not stop here; broaden your watchlist now so you are not reacting after the next move is already priced in.

• Target potential mispricing by scanning companies that combine quality with attractive valuations using our 51 high quality undervalued stocks.
• Prioritise resilience by checking out companies screened for strong finances and healthy balance sheets through our solid balance sheet and fundamentals stocks screener (44 results).
• Spot underfollowed opportunities before they are widely talked about by reviewing our screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.